FDA ap­proves Bio­gen’s ALS drug tofersen, paving new road for ac­cel­er­at­ed path­way in neu­ro dis­eases

The FDA grant­ed ac­cel­er­at­ed ap­proval to Bio­gen’s treat­ment for a rare type of amy­otroph­ic lat­er­al scle­ro­sis, or ALS, giv­ing a small sub­set of pa­tients a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER